WEBVTT

00:00:00.000 --> 00:00:04.070
<v Wren>Compass says one more dose keeps depression relief going a full year.

00:00:04.230 --> 00:00:12.975
<v Ash>That's 52-week Phase 3 data, and a 2027 launch is in sight. Before, the benefit lasted to 6 months.

00:00:13.135 --> 00:00:22.630
<v Wren>But the headline effect was modest, 3.8 points on a depression scale over 1 mg. And this follow-up is open-label, so everyone knew their dose.

00:00:22.790 --> 00:00:31.610
<v Ash>Still, it's over 1,000 patients, and two doses beat one. Plus a priority voucher cuts FDA review to 1-2 months.

00:00:31.770 --> 00:00:37.315
<v Wren>Yeah, but the extra-dose benefit is just company-reported, open-label data. Grain of salt.

00:00:37.475 --> 00:00:41.745
<v Ash>So it's the FDA decision that settles it, not this readout.

00:00:41.905 --> 00:00:44.125
<v Wren>Full tracker's at DreamLab Research.